论文部分内容阅读
我们自1982年4月开始,对猪脾及自猪脾制备的转移因子(TF(Ⅱ)]进行了一系列实验室和临床研究,并与人脾及人脾转移因子[TF(Ⅰ)]进行了比较。实验室研究包括:猪脾与人脾的组织学和细胞学、猪与人的血清HBsAg检查、TF(Ⅱ)与TF(Ⅰ)的游离氨基酸含量、肽类含量、戊糖与去氧戊糖含量、pH、紫外吸收光谱、生物活性、对培养中的细胞影响以及动物安全试验等,表明猪脾与人脾具有相似的组织结构及所含T淋巴细胞比率;54只猪血清HBsAg全部(-);TF(Ⅱ)与TF(Ⅰ)的生化组分及生物活性基本相同;对活细胞及实验动物均不具毒性。临床治疗包括:支气管哮喘、带状疱疹、急、慢性咽喉炎、人体放、化疗副反应、使OT皮试由(-)转(+)以及几种其它疾病的观察,均获得疗效。认为,TF(Ⅱ)完全可取代以人的组织或细胞为原材料所制备的转移因子,且前者优于后者。
We started a series of laboratory and clinical studies of porcine spleen and transfer factor (TF (II)) prepared from porcine spleen since April 1982. We have also conducted a series of laboratory and clinical studies with human spleen and human splenic transfer factor [TF (I)] The laboratory studies included histology and cytology of swine spleen and human spleen, serum HBsAg of swine and human, free amino acid content of TF (Ⅱ) and TF (Ⅰ), peptide content, pentose and Deoxy pentose content, pH, UV absorption spectra, biological activity, cell culture in culture and animal safety tests showed that the spleen and human spleen have a similar organizational structure and contained T lymphocyte ratio; 54 pig serum HBsAg all (-); TF (Ⅱ) and TF (Ⅰ) biochemical components and biological activity is basically the same; on living cells and laboratory animals are not toxic clinical treatment include: bronchial asthma, shingles, acute and chronic throat Inflammation, human body radiotherapy and chemotherapy side effects, the OT skin test by (-) transfer (+) and several other diseases observed, have been treated effect that TF (Ⅱ) can completely replace the human tissue or cells as raw materials The prepared transfer factor, and the former is better than the latter.